← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Calder Biosciences, Inc.
Brooklyn, NY
$6,811,750
Total funding
4
Grants
Funding over time
peak $1.8M · FY2017–22$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,811,750 · 4
By mechanism
R44$6,212,008 · 3
R43$599,742 · 1
Investigators at Calder Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$989,026
R44 · FY2021 · AG
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$986,704
R44 · FY2018 · AG
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$984,686
R44 · FY2022 · AG
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$939,591
R44 · FY2020 · AG
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$887,615
R44 · FY2020 · AG
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$650,899
R44 · FY2017 · AI
A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA$374,928
R44 · FY2019 · AG
An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination$299,955
R43 · FY2019 · AI
An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination$299,787
R43 · FY2018 · AI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence$299,740
R44 · FY2019 · AG
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine$98,819
R44 · FY2017 · AI